Vito Michele Fazio

ORCID: 0000-0002-7751-1867
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Epigenetics and DNA Methylation
  • MicroRNA in disease regulation
  • Lung Cancer Treatments and Mutations
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Cancer-related molecular mechanisms research
  • Cancer-related gene regulation
  • RNA modifications and cancer
  • Immunotherapy and Immune Responses
  • Monoclonal and Polyclonal Antibodies Research
  • Axon Guidance and Neuronal Signaling
  • Renal cell carcinoma treatment
  • RNA Interference and Gene Delivery
  • Neuroendocrine Tumor Research Advances
  • Lung Cancer Research Studies
  • Virus-based gene therapy research
  • Renal and related cancers
  • Genomics, phytochemicals, and oxidative stress
  • CRISPR and Genetic Engineering
  • Cancer-related Molecular Pathways
  • Glutathione Transferases and Polymorphisms
  • Genomics and Chromatin Dynamics
  • Microbial Inactivation Methods
  • Cancer Cells and Metastasis
  • Histone Deacetylase Inhibitors Research

Università Campus Bio-Medico
2016-2025

Istituto di Farmacologia Traslazionale
2020-2025

National Research Council
2020-2025

Istituti di Ricovero e Cura a Carattere Scientifico
2014-2024

Casa Sollievo della Sofferenza
2015-2024

PCR Oncology
2013-2023

Sapienza University of Rome
1987-2021

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2021

University of Milan
2021

Frederick National Laboratory for Cancer Research
2018

Martin Peifer Lynnette Fernández-Cuesta Martin L. Sos Julie George Danila Seidel and 88 more Lawryn H. Kasper Dennis Plenker Frauke Leenders Ruping Sun Thomas Zander Roopika Menon Mirjam Koker Ilona Dahmen Christian Müller Vincenzo Di Cerbo Hans‐Ulrich Schildhaus Janine Altmüller Ingelore Baessmann Christian Becker Bram De Wilde Jo Vandesompele Diana Böhm Sascha Ansén Franziska Gabler Ines Wilkening Stefanie Heynck Johannes M. Heuckmann Xin Lü Scott L. Carter Kristian Cibulskis Shantanu Banerji Gad Getz Kwon-Sik Park Daniel Rauh Christian Grütter Matthias Fischer Laura Pasqualucci Gavin Wright Zoe Wainer Prudence A. Russell Iver Petersen Yuan Chen Erich Stoelben Corinna Ludwig Philipp A. Schnabel Hans Hoffmann Thomas Muley Michael Brockmann Walburga Engel-Riedel Lucia Anna Muscarella Vito Michele Fazio Harry J.M. Groen Wim Timens Hannie Sietsma Erik Thunnissen Egbert F. Smit Daniëlle A.M. Heideman Peter J.F. Snijders Federico Cappuzzo Claudia Ligorio Stefania Damiani John K. Field Steinar Solberg Odd Terje Brustugun Marius Lund‐Iversen Jörg Sänger Joachim H. Clement Alex Soltermann Holger Moch Walter Weder Benjamin Solomon Jean‐Charles Soria Pierre Validire Benjamin Besse Élisabeth Brambilla Christian Brambilla Sylvie Lantuéjoul Philippe Lorimier Peter M. Schneider Michael Hallek William Pao Matthew Meyerson Julien Sage Jay Shendure Robert C. Schneider Reinhard Büttner Jürgen Wolf Peter Nürnberg Sven Perner Lukas C. Heukamp Paul K. Brindle Stefan A. Haas Roman K. Thomas

10.1038/ng.2396 article EN Nature Genetics 2012-09-02

Colorectal cancer (CRC) is a major health problem in industrialized countries. Although inflammation-linked carcinogenesis well accepted concept and often observed within the gastrointestinal tract, underlying mechanisms remain to be elucidated. Inflammation can indeed provide initiating promoting stimuli mediators, generating tumour-prone microenvironment. Many murine models of sporadic inflammation-related colon have been developed last decade, including chemically induced CRC models,...

10.4103/1477-3163.78279 article EN Journal of Carcinogenesis 2011-01-01

We discovered a novel somatic gene fusion, CD74-NRG1, by transcriptome sequencing of 25 lung adenocarcinomas never smokers. By screening 102 negative for known oncogenic alterations, we found four additional fusion-positive tumors, all which were the invasive mucinous subtype. Mechanistically, CD74-NRG1 leads to extracellular expression EGF-like domain NRG1 III-β3, thereby providing ligand ERBB2-ERBB3 receptor complexes. Accordingly, ERBB2 and ERBB3 was high in index case, phospho-ERBB3...

10.1158/2159-8290.cd-13-0633 article EN Cancer Discovery 2014-01-28

The KEAP1/Nrf2 pathway is a master regulator of several redox-sensitive genes implicated in resistance tumor cells against chemotherapeutic drugs. Recent data suggest that epigenetic mechanisms may play pivotal role the regulation KEAP1 expression. We performed comprehensive genetic and analysis gene 47 non-small cell lung cancer tissues normal specimens. Promoter methylation was using quantitative specific PCR assay real time. Methylation at promoter region detected 22 out NSCLCs (47%) none...

10.4161/epi.6.6.15773 article EN Epigenetics 2011-06-01

Abstract Purpose: In an effort to additionally determine the global patterns of CpG island hypermethylation in sporadic breast cancer, we searched for aberrant promoter methylation at 10 gene loci 54 primary cancer and benign lesions. Experimental Design: Genomic DNA sodium bisulfate converted from malignant tissues was used as template methyl-specific PCR BRCA1, p16, ESR1, GSTP1, TRβ1, RARβ2, HIC1, APC, CCND2, CDH1 genes. Results: The majority (85%) showed least 1 tested with half them...

10.1158/1078-0432.ccr-04-0555 article EN Clinical Cancer Research 2004-08-15

A new human retrovirus was isolated from a continuous cell line derived patient with CD4 + Tac - cutaneous T lymphoma/leukemia. This virus is related to but distinct leukemia/lymphoma types I and II (HTLV-I HTLV-II) immunodeficiency (HIV-1). With the use of fragment provirus cloned one leukemia, closely sequences were found in DNA tumor cells seven other patients same disease; these only distantly HTLV-I. The phenotype clinical course disease clearly distinguishable leukemia associated All...

10.1126/science.2825353 article EN Science 1987-12-11

In light with the view that KEAP1 loss of function may impact tumour behavior and modify response to chemotherapeutical agents, we sought determine whether gene is epigenetically regulated in malignant gliomas. We developed a Quantitative Methylation Specific PCR (QMSP) assay analyze 86 gliomas 20 normal brain tissues. The discriminatory power was assessed by Receiving Operating Characteristics (ROC) curve analysis. AUC value 0.823 (95%CI: 0.764-0.883) an optimal cut off 0.133 yielding 74%...

10.4161/epi.6.3.14408 article EN Epigenetics 2011-03-01

Keap1 (Kelch-like ECH-associated protein 1) is an adaptor that mediates the ubiquitination/degradation of genes regulating cell survival and apoptosis under oxidative stress conditions. We determined methylation status KEAP1 promoter in 102 primary breast cancers, 14 pre-invasive lesions, 38 paired normal tissues 6 from reductive mammoplasty by quantitative specific PCR (QMSP). Aberrant was detected 52 out cancer cases (51%) 10 lesions (71%). No mutations gene were identified 20 analyzed...

10.4161/epi.23319 article EN Epigenetics 2012-12-18

The Keap1/Nrf2 pathway is a master regulator of the cellular redox state through induction several antioxidant defence genes implicated in chemotherapeutic drugs resistance tumor cells. An increasing body evidence supports key role for kidney diseases and renal cell carcinoma (RCC), but data concerning molecular basis clinical effect its deregulation remain incomplete.Here we present profiling KEAP1 NFE2L2 five different Renal Cell Carcinoma histotypes by analysing 89 tumor/normal paired...

10.18632/oncotarget.14492 article EN Oncotarget 2017-01-04

Abstract Purpose: EphA2 receptor is involved in multiple cross-talks with other cellular networks, including EGFR, FAK, and VEGF pathways, which it collaborates to stimulate cell migration, invasion, metastasis. Colorectal cancer (CRC) overexpression has also been correlated stem-like properties of cells tumor malignancy. We investigated the molecular cross-talk miRNAs modulation EGFR pathways. explored role EphA2/EGFR pathway mediators as prognostic factors or predictors cetuximab benefit...

10.1158/1078-0432.ccr-16-0709 article EN Clinical Cancer Research 2016-07-12

Gliomas represent a disparate group of tumours for which there are to date no cure. Thus, is recognized need new diagnostic and therapeutic approaches based on increased understanding their molecular nature. We performed the comparison microRNA (miRNA) profile 8 WHO grade II gliomas 24 higher (2 III 22 glioblastomas) by using Affymetrix GeneChip miRNA Array v. 1.0. A relative quantification method (RT-qPCR) with standard curve was used confirm signature resulted array analysis. The...

10.1371/journal.pone.0108950 article EN cc-by PLoS ONE 2014-10-03

Abstract Aberrant promoter methylation of several known or putative tumor suppressor genes occurs frequently during carcinogenesis, and this epigenetic change has been considered as a potential molecular marker for cancer. We examined the status nine (APC, CDH1, CTNNB1, TIMP3, ESR1, GSTP1, MGMT, THBS1, TMS1), by quantitative specific PCR. Synchronous preinvasive lesions (atypical ductal hyperplasia and/or carcinoma in situ) invasive breast from 52 patients, together with pure 24 patients 12...

10.1158/1055-9965.epi-08-0821 article EN Cancer Epidemiology Biomarkers & Prevention 2009-10-01

Background: Plasmid DNA vaccination combined with electroporation (EP) provides a promising approach for the prevention of infectious diseases and cancer immunotherapy. This technology has been described as being effective in activating humoural cellular immune response host well enhancing expression encoded antigen. Several reports showed EP adjuvant-like properties when plasmid injection although effect absence not investigated. Objective: The aim this study is to clarify whether...

10.1517/14712598.8.11.1645 article EN Expert Opinion on Biological Therapy 2008-10-10

// Jianmin Wang 1,* , Antonios Papanicolau-Sengos 2,* Sreenivasulu Chintala 3,10,* Lei Wei 1 Biao Liu Qiang Hu Kiersten Marie Miles 2 Jeffrey M. Conroy Sean T. Glenn 4 Manuela Costantini 5,8,9 Cristina Magi-Galluzzi 6 Sabina Signoretti 7 Toni Choueiri Michele Gallucci 5 Steno Sentinelli Vito Fazio 8 Maria Luana Poeta 9 Song Carl Morrison and Roberto Pili 3,10 Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA Pathology Center for Personalized...

10.18632/oncotarget.9093 article EN Oncotarget 2016-04-28

Abstract miR-9 was initially identified as an epigenetically regulated miRNA in tumours, but inconsistent findings have been reported so far. We analysed the expression of miR-9-5p, miR-9-3p, pri-miRs and MIR9 promoters methylation status 131 breast cancer cases 12 normal tissues (NBTs). The both mature miRs increased tumours compared to NBTs (P < 0.001) negatively correlated with ER protein ( P = 0.005 0.003, for miR-9-3p miR-9-5p respectively). In addition, showed a significant negative...

10.1038/srep45283 article EN cc-by Scientific Reports 2017-03-27
Coming Soon ...